Decrease in choroidal blood flow after half and one-third dose verteporfin photodynamic therapy for chronic central serous chorioretinopathy.
Central choroidal thickness
Central serous chorioretinopathy
Choroidal blood flow
Laser speckle flowgraphy
Journal
BMC ophthalmology
ISSN: 1471-2415
Titre abrégé: BMC Ophthalmol
Pays: England
ID NLM: 100967802
Informations de publication
Date de publication:
31 May 2021
31 May 2021
Historique:
received:
13
01
2021
accepted:
19
04
2021
entrez:
31
5
2021
pubmed:
1
6
2021
medline:
2
6
2021
Statut:
epublish
Résumé
The effect of various reduced doses of verteporfin photodynamic therapy (PDT) on choroidal blood flow in chronic central serous chorioretinopathy (CSC) remains unclear. Therefore, this study aimed to evaluate choroidal blood flow after half-dose PDT (1/2PDT) and one-third dose PDT (1/3PDT) with verteporfin for chronic CSC using laser speckle flowgraphy and spectral-domain optical coherence tomography. Twenty-seven eyes of 27 patients with serous retinal detachment (SRD) caused by chronic CSC for more than 6 months were included in this study. Patients were divided into the 1/2PDT (n = 12; January 2018 to July 2019) and 1/3PDT (n = 15; August 2016 to December 2017) groups based on the treatment period. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), central choroidal thickness (CCT), and mean blur rate in the macular area (m-MBR) and optic nerve head (ONH-MBR) were obtained using laser speckle flowgraphy and evaluated at baseline (pre-treatment), and 2 weeks, 1 month, 3 months, and 6 months after treatment. We found that SRD disappeared after 1 month in 92 and 93% of patients' eyes in the 1/2PDT and 1/3PDT groups, respectively. Recurrence of SRD was observed in one eye at the 6-month follow-up after 1/2PDT and two eyes at the 3-month follow-up after 1/3PDT. No significant improvement was observed in baseline BCVA in the 1/3PDT and 1/2PDT groups. The average m-MBR against baseline significantly decreased at 2 weeks and 1, 3, and 6 months in the 1/2PDT group. The average m-MBR against baseline decreased significantly only at the 2 weeks follow-up in the 1/3PDT group. The average rate of change in the CCT against baseline decreased significantly throughout for up to 6 months in the 1/2PDT group and for up to 3 months in the 1/3PDT group. No significant fluctuation was observed in the ONH-MBR. Here, PDT significantly affected choroidal blood flow depending on the verteporfin dose in chronic CSC. This trial was retrospectively registered ( UMIN000026850 ; Approval date 03/04/2017).
Sections du résumé
BACKGROUND
BACKGROUND
The effect of various reduced doses of verteporfin photodynamic therapy (PDT) on choroidal blood flow in chronic central serous chorioretinopathy (CSC) remains unclear. Therefore, this study aimed to evaluate choroidal blood flow after half-dose PDT (1/2PDT) and one-third dose PDT (1/3PDT) with verteporfin for chronic CSC using laser speckle flowgraphy and spectral-domain optical coherence tomography.
METHODS
METHODS
Twenty-seven eyes of 27 patients with serous retinal detachment (SRD) caused by chronic CSC for more than 6 months were included in this study. Patients were divided into the 1/2PDT (n = 12; January 2018 to July 2019) and 1/3PDT (n = 15; August 2016 to December 2017) groups based on the treatment period. The best-corrected visual acuity (BCVA), central retinal thickness (CRT), central choroidal thickness (CCT), and mean blur rate in the macular area (m-MBR) and optic nerve head (ONH-MBR) were obtained using laser speckle flowgraphy and evaluated at baseline (pre-treatment), and 2 weeks, 1 month, 3 months, and 6 months after treatment.
RESULTS
RESULTS
We found that SRD disappeared after 1 month in 92 and 93% of patients' eyes in the 1/2PDT and 1/3PDT groups, respectively. Recurrence of SRD was observed in one eye at the 6-month follow-up after 1/2PDT and two eyes at the 3-month follow-up after 1/3PDT. No significant improvement was observed in baseline BCVA in the 1/3PDT and 1/2PDT groups. The average m-MBR against baseline significantly decreased at 2 weeks and 1, 3, and 6 months in the 1/2PDT group. The average m-MBR against baseline decreased significantly only at the 2 weeks follow-up in the 1/3PDT group. The average rate of change in the CCT against baseline decreased significantly throughout for up to 6 months in the 1/2PDT group and for up to 3 months in the 1/3PDT group. No significant fluctuation was observed in the ONH-MBR.
CONCLUSIONS
CONCLUSIONS
Here, PDT significantly affected choroidal blood flow depending on the verteporfin dose in chronic CSC.
TRIAL REGISTRATION
BACKGROUND
This trial was retrospectively registered ( UMIN000026850 ; Approval date 03/04/2017).
Identifiants
pubmed: 34053440
doi: 10.1186/s12886-021-01980-w
pii: 10.1186/s12886-021-01980-w
pmc: PMC8165776
doi:
Substances chimiques
Photosensitizing Agents
0
Verteporfin
0X9PA28K43
Types de publication
Clinical Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
241Références
Oman J Ophthalmol. 2018 May-Aug;11(2):103-112
pubmed: 29930442
Retina. 2006 Feb;26(2):239-42
pubmed: 16467692
Prog Retin Eye Res. 2010 Mar;29(2):144-68
pubmed: 20044062
Graefes Arch Clin Exp Ophthalmol. 2015 Apr;253(4):609-17
pubmed: 25619665
Graefes Arch Clin Exp Ophthalmol. 2019 Oct;257(10):2155-2161
pubmed: 31367848
Eye (Lond). 2012 May;26(5):640-9
pubmed: 22573069
Clin Exp Ophthalmol. 2014 Mar;42(2):139-50
pubmed: 23777505
JAMA Ophthalmol. 2015 Mar;133(3):333-40
pubmed: 25555191
Br J Ophthalmol. 2017 Apr;101(4):433-437
pubmed: 27388248
Retina. 2009 Sep;29(8):1155-61
pubmed: 19629018
Br J Ophthalmol. 2013 Jun;97(6):775-80
pubmed: 23532615
Graefes Arch Clin Exp Ophthalmol. 2012 Sep;250(9):1275-81
pubmed: 22350058
Klin Monbl Augenheilkd. 2016 Jul;233(7):860-3
pubmed: 26609673
Jpn J Ophthalmol. 2009 Jan;53(1):52-56
pubmed: 19184311
Clin Ophthalmol. 2016 Dec 20;11:39-46
pubmed: 28053499
Am J Ophthalmol. 2020 Sep;217:104-113
pubmed: 32360342
J Ophthalmic Vis Res. 2016 Jan-Mar;11(1):66-9
pubmed: 27195088
Br J Ophthalmol. 2018 Sep;102(9):1218-1225
pubmed: 29301768
Ophthalmology. 2015 Mar;122(3):555-61
pubmed: 25444637
Ophthalmology. 2019 Apr;126(4):576-588
pubmed: 30659849
Indian J Ophthalmol. 2016 Oct;64(10):747-751
pubmed: 27905337
Am J Ophthalmol. 2006 Oct;142(4):680-3
pubmed: 17011867
Prog Retin Eye Res. 2019 Nov;73:100770
pubmed: 31319157
PLoS One. 2016 Sep 16;11(9):e0163104
pubmed: 27636093
Ophthalmic Surg Lasers Imaging Retina. 2015 Jan;46(1):25-32
pubmed: 25559505
Ophthalmologica. 2005 Jul-Aug;219(4):202-5
pubmed: 16088238
BMC Ophthalmol. 2014 Nov 25;14:145
pubmed: 25421855
Invest Ophthalmol Vis Sci. 2015 Oct;56(11):6515-22
pubmed: 26447987
Ophthalmology. 2018 Oct;125(10):1547-1555
pubmed: 29776672
Am J Ophthalmol. 2009 Jul;148(1):105-10.e1
pubmed: 19327740
Retina. 1996;16(3):203-13
pubmed: 8789858
Retina. 2011 Oct;31(9):1921-7
pubmed: 21878850
Trans Am Ophthalmol Soc. 2015;113:T8
pubmed: 26755855
Br J Ophthalmol. 2019 Nov;103(11):1615-1618
pubmed: 30602447
Retina. 2016 Sep;36(9):1652-7
pubmed: 26934451
Acta Ophthalmol. 2016 Sep;94(6):565-72
pubmed: 27149889
Br J Ophthalmol. 2003 Dec;87(12):1453-8
pubmed: 14660450